Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review

[1]  K. Wilkins,et al.  An update on cancer survival. , 2010, Health reports.

[2]  U. Mansmann,et al.  Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer , 2010, Tumor Biology.

[3]  Tibor Schuster,et al.  Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.

[4]  Alvin C. Silva,et al.  Risk factors for pancreatic adenocarcinoma and prospects for screening. , 2010, Gastroenterology & hepatology.

[5]  N. Shigemoto,et al.  Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer , 2010, Annals of Surgical Oncology.

[6]  M. Duffy,et al.  Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  H. Eguchi,et al.  Serum CA19–9 Alterations During Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Invasive Ductal Carcinoma of the Pancreas as an Indicator for Therapeutic Selection and Survival , 2010, Annals of surgery.

[8]  Jeffrey E. Lee,et al.  Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation , 2010, Annals of Surgical Oncology.

[9]  U. Mansmann,et al.  Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer , 2010, Clinical Cancer Research.

[10]  Y. Cho,et al.  Can preoperative CA19‐9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? , 2009, Journal of gastroenterology and hepatology.

[11]  Yusuke Nakamura,et al.  Serum REG4 Level Is a Predictive Biomarker for the Response to Preoperative Chemoradiotherapy in Patients With Pancreatic Cancer , 2009, Pancreas.

[12]  J. Maurel,et al.  CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone , 2009, British Journal of Cancer.

[13]  F. Roviello,et al.  CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. , 2009, American journal of surgery.

[14]  D. Ziogas,et al.  Highly elevated serum levels of CA 19-9 in choledocholithiasis: a case report , 2009, Cases journal.

[15]  M. Reni,et al.  Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma , 2009, Cancer.

[16]  H. Ramesh,et al.  CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? , 2009, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[17]  K. Lillemoe,et al.  Very High Serum CA 19-9 Levels: A Contraindication to Pancreaticoduodenectomy? , 2009, Journal of Gastrointestinal Surgery.

[18]  S. Hanash,et al.  A Compendium of Potential Biomarkers of Pancreatic Cancer , 2009, PLoS medicine.

[19]  K. Yamashita,et al.  Preoperative Serum CA19-9 and Dissected Peripancreatic Tissue Margin as Determiners of Long-Term Survival in Pancreatic Cancer , 2009, Annals of Surgical Oncology.

[20]  A. Rosemurgy,et al.  CA 19-9 Velocity Predicts Disease-Free Survival and Overall Survival After Pancreatectomy of Curative Intent , 2009, Journal of Gastrointestinal Surgery.

[21]  M. Gönen,et al.  Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma , 2008, Annals of Surgical Oncology.

[22]  J. Neoptolemos,et al.  Preoperative CA19-9 Levels and Lymph Node Ratio Are Independent Predictors of Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma , 2008, Digestive Surgery.

[23]  Yun Lu,et al.  Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. , 2008, World journal of gastroenterology.

[24]  B. Dörken,et al.  Decrease of CA 19-9 in patients with advanced pancreatic cancer (APC) undergoing chemotherapy predicts survival time , 2008 .

[25]  R. Wolff,et al.  Serum CA 19–9 level as a surrogate marker for prognosis in locally advanced pancreatic cancer (LAPC) , 2008 .

[26]  D. M. Lloyd,et al.  Elevation of Carbohydrate Antigen 19.9 in Benign Hepatobiliary Conditions and Its Correlation with Serum Bilirubin Concentration , 2008, Digestive Diseases and Sciences.

[27]  W. Scheithauer,et al.  CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. , 2008, The Lancet. Oncology.

[28]  J. Neoptolemos,et al.  Carbohydrate antigen 19·9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy , 2007, The British journal of surgery.

[29]  Yupei Zhao,et al.  Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. , 2007, Hepatobiliary & pancreatic diseases international : HBPD INT.

[30]  T. Misawa,et al.  Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. , 2007, Journal of hepato-biliary-pancreatic surgery.

[31]  C. Logsdon,et al.  Progress on molecular markers of pancreatic cancer , 2007, Current opinion in gastroenterology.

[32]  J. Choi,et al.  The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. , 2007, The Journal of surgical research.

[33]  R. Kannagi.  Carbohydrate antigen sialyl Lewis a--its pathophysiological significance and induction mechanism in cancer progression. , 2007, Chang Gung medical journal.

[34]  A. Siriwardena,et al.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[35]  J. P. Esquete,et al.  Evaluation of the Bilio-Pancreatic Region Using Endoscopic Ultrasonography in Patients Referred with and without Abdominal Pain and CA 19-9 Serum Level Elevation , 2007 .

[36]  N. Duraker,et al.  CEA, CA 19‐9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice , 2007, Journal of surgical oncology.

[37]  T. Ertan,et al.  Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. , 2006, Canadian journal of surgery. Journal canadien de chirurgie.

[38]  D. Finkelstein,et al.  Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  G. Uomo,et al.  Persistent elevation of serum CA 19-9 with no evidence of malignant disease. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[40]  V. Velanovich,et al.  Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis. , 2006, American journal of surgery.

[41]  D. Chan,et al.  Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9 , 2006, Clinical Cancer Research.

[42]  N. Alvarez-Aguila,et al.  Adjusted carbohydrate antigen 19-9. Correlation with histological grade in pancreatic adenocarcinoma. , 2005, Anticancer research.

[43]  M. Tempero,et al.  Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer , 2005, British Journal of Cancer.

[44]  Thomas Howard,et al.  Comparison of Endoscopic Ultrasonography and Multidetector Computed Tomography for Detecting and Staging Pancreatic Cancer , 2004, Annals of Internal Medicine.

[45]  H. Tao,et al.  Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. , 2004, Hepatobiliary & pancreatic diseases international : HBPD INT.

[46]  I. Meszoely,et al.  Undetectable Preoperative Levels of Serum CA 19-9 Correlate with Improved Survival for Patients with Resectable Pancreatic Adenocarcinoma , 2004, Annals of Surgical Oncology.

[47]  B. Yeole,et al.  Population-based survival from cancers having a poor prognosis in Mumbai (Bombay), India. , 2004, Asian Pacific journal of cancer prevention : APJCP.

[48]  J. K. Lee,et al.  Clinical usefulness of carbohydrate antigen 19‐9 as a screening test for pancreatic cancer in an asymptomatic population , 2004, Journal of gastroenterology and hepatology.

[49]  T. Sauerbruch,et al.  Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine , 2003, British Journal of Cancer.

[50]  R. Lamerz,et al.  Are Serial CA 19-9 Kinetics Helpful in Predicting Survival in Patients with Advanced or Metastatic Pancreatic Cancer Treated with Gemcitabine and Cisplatin? , 2003, Oncology Research and Treatment.

[51]  R. Bold,et al.  Utility of tumor markers in determining resectability of pancreatic cancer. , 2003, Archives of surgery.

[52]  N. Willich,et al.  CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. , 2003, Anticancer research.

[53]  E. Saad,et al.  Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine , 2002, International journal of gastrointestinal cancer.

[54]  A. Duarte-Rojo,et al.  [Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer?]. , 2001, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[55]  H. Ueno,et al.  Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy , 2001, Cancer.

[56]  V. Keim,et al.  Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer , 2000, British Journal of Cancer.

[57]  T. Yoshikawa,et al.  Doubling time of serum CA 19‐9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis , 1999, Journal of surgical oncology.

[58]  S. Myung,et al.  A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve , 1999, American Journal of Gastroenterology.

[59]  C. Su,et al.  Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers. , 1999, Journal of the American College of Surgeons.

[60]  S. Nomoto,et al.  Clinical usefulness of CA-19-9 in pancreatic carcinoma. , 1998, Seminars in surgical oncology.

[61]  B. Eisenberg,et al.  Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas , 1997, Annals of Surgical Oncology.

[62]  J. Furuse,et al.  CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. , 1997, Hepato-gastroenterology.

[63]  W. Schlosser,et al.  Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms , 1997, Journal of Gastrointestinal Surgery.

[64]  C. Willett,et al.  CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. , 1996, American journal of surgery.

[65]  T. Homma,et al.  CA19‐9 as a Screening and Diagnostic Tool in Symptomatic Patients: The Japanese Experience , 1994, Pancreas.

[66]  V. Zurawski,et al.  Comparison of Preoperative Serum CA19‐9 Levels with Results of Diagnostic Imaging Modalities in Patients Undergoing Laparotomy for Suspected Pancreatic or Gallbladder Disease , 1994, Pancreas.

[67]  C. Haglund,et al.  The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. , 1994, British Journal of Cancer.

[68]  C. Pasquali,et al.  CA 19‐9 as a prognostic index after resection for pancreatic cancer , 1993, Journal of surgical oncology.

[69]  M. Plebani,et al.  Extra‐hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases , 1992, European journal of clinical investigation.

[70]  W. Steinberg.  The clinical utility of the CA 19-9 tumor-associated antigen. , 1990, The American journal of gastroenterology.

[71]  D. Pleskow,et al.  Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. , 1989, Annals of internal medicine.

[72]  H. Aste,et al.  CA 19‐9 and CA 50 in Benign and malignant pancreatic and biliary diseases , 1988, Cancer.

[73]  F. Safi,et al.  High Sensitivity and Specificity of CA 19‐9 for Pancreatic Carcinoma in Comparison to Chronic Pancreatitis. Serological and Immunohistochemical Findings , 1987, Pancreas.

[74]  M. Herlyn,et al.  Colorectal carcinoma antigens detected by hybridoma antibodies , 1979, Somatic cell genetics.

[75]  J. Yim,et al.  Increased CA 19-9 level in patients without malignant disease , 2009, Clinical Chemistry and Laboratory Medicine.

[76]  Jaw-Town Lin,et al.  Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. , 2006, Hepato-gastroenterology.

[77]  M. Plebani,et al.  Alterations in bilirubin metabolism during extra- and intrahepatic cholestasis , 2004, The clinical investigator.

[78]  T. Ørntoft,et al.  Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. , 1999, Clinical chemistry.

[79]  H. Pitt,et al.  CA 19-9 in pancreatic cancer. , 1998, Surgical oncology clinics of North America.

[80]  H. Gogas,et al.  Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? , 1998, British Journal of Cancer.